Total Payments
$191,692
2024 Payments
$37,765
Companies
13
Transactions
101
Medicare Patients
191
Medicare Billing
$19,522
Payment Breakdown by Category
Research$79,550 (41.5%)
Consulting$51,739 (27.0%)
Travel$29,360 (15.3%)
Other$28,325 (14.8%)
Food & Beverage$2,648 (1.4%)
Education$69.98 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $79,550 | 16 | 41.5% |
| Consulting Fee | $51,739 | 17 | 27.0% |
| Travel and Lodging | $29,360 | 35 | 15.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $28,325 | 4 | 14.8% |
| Food and Beverage | $2,648 | 27 | 1.4% |
| Education | $69.98 | 2 | 0.0% |
Payments by Type
General
$112,143
85 transactions
Research
$79,550
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI PASTEUR INC. | $61,398 | 20 | $0 (2024) |
| BioFire Diagnostics, LLC | $55,436 | 3 | $0 (2023) |
| PFIZER INC. | $35,951 | 28 | $0 (2024) |
| Gilead Sciences, Inc. | $14,085 | 15 | $0 (2023) |
| GlaxoSmithKline, LLC. | $10,425 | 6 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $4,853 | 6 | $0 (2024) |
| Janssen Global Services, LLC | $4,361 | 8 | $0 (2023) |
| Merck Sharp & Dohme LLC | $2,142 | 3 | $0 (2024) |
| Abbott Laboratories | $1,125 | 1 | $0 (2019) |
| AstraZeneca UK Limited | $910.00 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $37,765 | 20 | SANOFI PASTEUR INC. ($17,257) |
| 2023 | $91,734 | 26 | BioFire Diagnostics, LLC ($55,436) |
| 2022 | $5,230 | 5 | PFIZER INC. ($4,470) |
| 2021 | $9,651 | 6 | PFIZER INC. ($7,200) |
| 2020 | $7,834 | 4 | PFIZER INC. ($7,800) |
| 2019 | $2,534 | 6 | PFIZER INC. ($1,409) |
| 2018 | $17,865 | 13 | Sanofi Pasteur Inc. ($11,084) |
| 2017 | $19,079 | 21 | SANOFI PASTEUR INC. ($9,668) |
All Payment Transactions
101 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $910.00 | General |
| 11/20/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| 11/08/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $4,322.50 | General |
| 10/28/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $44.99 | General |
| 10/18/2024 | SANOFI PASTEUR INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,787.50 | General |
| 10/17/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 10/17/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $141.12 | General |
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $131.33 | General |
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $120.52 | General |
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $86.03 | General |
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $51.33 | General |
| 10/09/2024 | SANOFI PASTEUR INC. | — | Consulting Fee | Cash or cash equivalent | $3,219.32 | General |
| 07/24/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,092.50 | General |
| 07/11/2024 | PFIZER INC. | ABRYSVO (Biological) | Travel and Lodging | In-kind items and services | $8,447.99 | General |
| Category: VACCINES | ||||||
| 07/11/2024 | PFIZER INC. | ABRYSVO (Biological) | Travel and Lodging | In-kind items and services | $405.00 | General |
| Category: VACCINES | ||||||
| 07/11/2024 | PFIZER INC. | ABRYSVO (Biological) | Travel and Lodging | In-kind items and services | $304.48 | General |
| Category: VACCINES | ||||||
| 07/11/2024 | PFIZER INC. | ABRYSVO (Biological) | Food and Beverage | In-kind items and services | $250.01 | General |
| Category: VACCINES | ||||||
| 07/02/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $300.00 | General |
| 03/15/2024 | SANOFI PASTEUR INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $4,250.00 | General |
| 12/15/2023 | PFIZER INC. | ABRYSVO (Biological) | — | In-kind items and services | $3,200.00 | Research |
| Study: RSV VACCINE PROTSUBUNIT PREF 2V CLINICAL PUBLICATION PROGRAM • Category: VACCINES | ||||||
| 10/03/2023 | PFIZER INC. | ABRYSVO (Biological) | — | In-kind items and services | $780.00 | Research |
| Study: RSV VACCINE PROTSUBUNIT PREF 2V CLINICAL PUBLICATION PROGRAM • Category: VACCINES | ||||||
| 08/02/2023 | BioFire Diagnostics, LLC | — | — | Cash or cash equivalent | $18,478.50 | Research |
| 08/02/2023 | BioFire Diagnostics, LLC | — | — | Cash or cash equivalent | $18,478.50 | Research |
| 08/02/2023 | BioFire Diagnostics, LLC | — | — | Cash or cash equivalent | $18,478.50 | Research |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESPIRATORY SYNCYTIAL VIRUS CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $8,580 | 4 |
| COVID19 VACC CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $6,420 | 3 |
| RSV VACCINE PROTSUBUNIT PREF 2V CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,980 | 2 |
| RSV VACCINE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,530 | 2 |
| PF06928316 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| Analysis of Semiquantitative bacterial PCR of sputum as measured by FilmArray Pneumonia Panel plus compared to conventional culture with clinical adjudication, serum procalcitonin, and whole blood transcriptional profiling | bioMerieux Inc | $664.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 18 | 30 | $8,850 | $1,859 |
| 2022 | 2 | 31 | 47 | $8,704 | $3,265 |
| 2021 | 5 | 99 | 144 | $22,288 | $10,678 |
| 2020 | 2 | 43 | 57 | $8,633 | $3,720 |
Total Patients
191
Total Services
278
Medicare Billing
$19,522
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 30 | $8,850 | $1,859 | 21.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 19 | 34 | $5,231 | $1,908 | 36.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 12 | 13 | $3,473 | $1,357 | 39.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 41 | 72 | $8,394 | $4,111 | 49.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 23 | 23 | $5,087 | $2,292 | 45.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 12 | 24 | $4,036 | $1,969 | 48.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 11 | 12 | $3,929 | $1,909 | 48.6% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 12 | 13 | $841.36 | $396.76 | 47.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 19 | 19 | $4,202 | $1,863 | 44.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 24 | 38 | $4,430 | $1,857 | 41.9% |
About Dr. Ann Falsey, MD
Dr. Ann Falsey, MD is a Infectious Disease healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1093740532.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ann Falsey, MD has received a total of $191,692 in payments from pharmaceutical and medical device companies, with $37,765 received in 2024. These payments were reported across 101 transactions from 13 companies. The most common payment nature is "" ($79,550).
As a Medicare-enrolled provider, Falsey has provided services to 191 Medicare beneficiaries, totaling 278 services with total Medicare billing of $19,522. Data is available for 4 years (2020–2023), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Rochester, NY
- Active Since 07/12/2006
- Last Updated 06/29/2023
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1093740532
Products in Payments
- NO PRODUCT DISCUSSED (Drug) $20,752
- ABRYSVO (Biological) $13,387
- COMIRNATY (Biological) $1,820
- FLUZONE QUADRIVALENT NORTHERN HEMISPHERE (Biological) $1,127
- CABENUVA (Drug) $177.61
- Cabenuva (Drug) $21.27
- JANUVIA (Drug) $15.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Rochester
Robin Patel, M.d, M.D
Infectious Disease — Payments: $270,548
Infectious Disease $270,548
Edward Walsh, Md, MD
Infectious Disease — Payments: $131,419
Infectious Disease $131,419
Emil Lesho, D.o, D.O
Infectious Disease — Payments: $65,937
Infectious Disease $65,937
Zelalem Temesgen, M.d, M.D
Infectious Disease — Payments: $56,223
Infectious Disease $56,223
Dr. Angela Branche, Md, MD
Infectious Disease — Payments: $50,957
Infectious Disease $50,957
William Valenti, Md, MD
Infectious Disease — Payments: $38,806
Infectious Disease $38,806